Highlights of weekly biotech stock moves

Chelsea Therapeutics International Inc. (NASDAQ:CHTP) was up $1.47 (61%) to $3.88 on Friday after FDA's Cardiovascular and Renal Drugs Advisory Committee voted on Thursday to recommend approval of Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH).

The 7-4 vote, with one abstention and one non-vote, came after the agency posted briefing documents online Tuesday that recommended against approval. The panel acknowledged concerns about the limited duration of efficacy data and a lack of long-term safety data, but concluded the available evidence of efficacy was sufficient to outweigh the concerns, particularly in light of the serious unmet medical need(see B11)...